Deep intronic MSH2 variant confirms Muir-Torre subtype of Lynch syndrome
Open Access
- 5 December 2025
- journal article
- case report
- Published by Elsevier in JID Innovations
- Vol. 6 (2) , 100438
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (FDN-148390)
- Canadian Institutes of Health Research (CP21/00038)
- Merck Canada
- Pfizer
- Instituto de Salud Carlos III (PI20/01721)
This publication has 18 references indexed in Scilit:
- Whole genome sequencing completes the molecular genetic testing workflow of patients with Lynch syndromenpj Genomic Medicine, 2025
- Noncoding Aberrations in Mismatch Repair Genes Underlie a Substantial Part of the Missing Heritability in Lynch SyndromeGastroenterology, 2022
- Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch SyndromeThe Journal of Molecular Diagnostics, 2020
- A practical guide to biomarkers for the evaluation of colorectal cancerLaboratory Investigation, 2019
- A squamous cell carcinoma in a young woman with Lynch syndromeFamilial Cancer, 2018
- Muir-Torre syndrome (MTS): An update and approach to diagnosis and managementJournal of the American Academy of Dermatology, 2016
- A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch SyndromeHereditary Cancer in Clinical Practice, 2015
- A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir–Torre variant of Lynch syndromeGenetics in Medicine, 2014
- The Frequency of Muir-Torre Syndrome Among Lynch Syndrome FamiliesJNCI: Journal of the National Cancer Institute, 2008
- Sebaceous gland tumors and internal malignancy in the context of Muir-Torre syndrome. A case report and review of the literatureWorld Journal of Surgical Oncology, 2006